Role Of Medium Chain Triglycerides (Axona®) In The Treatment Of Mild To Moderate Alzheimer’s Disease

This research review examined whether medium-chain triglycerides (MCTs) - a type of fat found in coconut oil and available as a supplement called Axona - could help treat Alzheimer's disease. The brain typically uses glucose (sugar) for energy, but in Alzheimer's patients, the brain's ability to use glucose becomes impaired early in the disease. MCTs can be converted by the liver into ketone bodies, which serve as an alternative fuel source that brain cells can use when glucose metabolism is compromised.

Clinical trials found that MCTs improved cognitive function in patients with mild to moderate Alzheimer's disease, but with an important caveat: the benefits were only seen in people who did not carry the APOE4 gene variant. People with APOE4 - which affects about 25% of the population - tend to have more severe Alzheimer's disease and showed no improvement with MCT treatment. The supplement was generally well-tolerated, with mild digestive side effects like diarrhea and stomach upset being the most common issues reported.

The metabolic approach of providing alternative brain fuel represents a promising strategy beyond current Alzheimer's medications, which only provide modest symptom relief without slowing disease progression. However, the treatment's effectiveness depends on genetic factors that aren't routinely tested in clinical practice. This research highlights how personalized medicine based on genetic profiles could optimize brain health interventions, though genetic testing would be needed to identify who might benefit most from MCT supplementation.